Vivozon Pharmaceutical KRX:082800KOSDAQ
비보존 제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked12since Sep 11
In Q2 2026, Vivozon Pharmaceutical reported revenue of ₩13.3bn, down 25.4% year on year, and an operating loss of ₩1.9bn. Vivozon Pharmaceutical (비보존 제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Share pledge Screener
Vivozon Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩13.3bn | -25.4% | −₩1.9bn margin −14.6% | −₩2.8bn |
| Q1 2026 | ₩14.1bn | -24.1% | −₩3.0bn margin −21.4% | −₩5.6bn |
| Q4 2025 derived | ₩16.2bn | -30.3% | −₩3.7bn margin −23.0% | −₩12.8bn |
| Q3 2025 | ₩6.8bn | -71.4% | −₩10.2bn margin −151.0% | −₩11.6bn |
| Q2 2025 | ₩17.8bn | -14.7% | −₩2.7bn margin −15.3% | −₩4.2bn |
| Q1 2025 | ₩18.6bn | -6.4% | −₩2.5bn margin −13.5% | −₩3.8bn |
| Q4 2024 derived | ₩23.3bn | +1.4% | ₩512m margin 2.2% | −₩8.7bn |
| Q3 2024 | ₩23.6bn | +32.2% | ₩1.3bn margin 5.4% | ₩256m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Vivozon Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Vivozon Pharmaceutical news Korean headlines
-
비보존, 글로벌 규제 대응 지원사업 선정
6 more on this story · 6 outlets
- 비보존, 글로벌 규제 대응 지원사업 다년도 수행기업 선정뉴스핌 · Sep 11 09:38
- [비보존] 한국보건산업진흥원 ‘2026년 글로벌 규제 대응 비용 지원사업’ 선정뉴스더보이스헬스케어 · Sep 11 09:50
- 비보존, 진흥원 ‘글로벌 규제 대응 비용 지원사업’ 선정SR타임스 · Sep 11 10:12
- 비보존, '어나프라주' 美 FDA 규제 지원사업 선정중소기업신문 · Sep 11 14:18
- 비보존제약 관계사 비보존, 보건산업진흥원 '글로벌 규제 대응 지원사업' 선정파이낸셜포스트 · Sep 11 16:31
- 비보존, 보건산업진흥원 '2026년 글로벌 규제 대응 비용 지원사업' 선정팜뉴스 · Sep 11 16:59